From £7.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £7.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

BREAKING DAMNING EXPOSE: Alpha Growth – the shambolic Prospectus is finally approved by the FCA but how and why? An essay in “not fit for purpose”.

By Tom Winnifrith | Saturday 18 December 2021


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


Alpha Growth Plc (ALGW) has finally had FCA approval of its Prospectus for the Placing that occurred 10 months ago in February 2021. The FCA is supposed to ensure that any Prospectus issued complies with the rules but it is apparent from a quick read that the Prospectus has not been properly updated throughout the document as many of the references are considerably out of date. It looks like someone at the FCA just wanted to remove the Prospectus from his or her to do list prior to the Christmas holidays rather than subject the document to appropriate and proper scrutiny or perhaps it was simply signed off after a long Christmas lunch. I cite below some examples of where the document hasn’t been properly updated.

Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

Saturday »

AVCT

Cassava, A warning to Avacta Sharehoders 

Friday »

ALU

Alumasc Group – a growth Buy

 

VCP

Victoria - The roll up unravels

 

HEMO

Hemogenyx is a short – target 0p

 

ECR

ECR, the timing is unfortunate

 

APH

Alliance Pharma – a recovery Buy?

Time left: 13:07:17